Taysha Gene Therapies, Inc. SEC filings TSHA
Taysha Gene Therapies, Inc. has 401 filings in SEC EDGAR's recent list, going back to May 4, 2020. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 22, 2026 | — |
| DEF 14A | Proxy statement | Apr 22, 2026 | Jun 1, 2026 |
| DEFA14A | Additional proxy material | Apr 21, 2025 | — |
| DEF 14A | Proxy statement | Apr 21, 2025 | Jun 2, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2025 | Jun 2, 2025 |
| DEFA14A | Additional proxy material | Apr 18, 2024 | — |
| DEF 14A | Proxy statement | Apr 18, 2024 | May 29, 2024 |
| DEF 14A | Proxy statement | Oct 5, 2023 | Nov 15, 2023 |
| PRE 14A | Preliminary proxy statement | Sep 21, 2023 | Nov 15, 2023 |
| DEFA14A | Additional proxy material | May 8, 2023 | — |
| DEF 14A | Proxy statement | May 8, 2023 | Jun 22, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 27, 2023 | Jun 22, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 17, 2022 |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 17, 2021 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TSHA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806310
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.